Brean Capital reiterated a Buy rating and $22.00 price target on Keryx Biopharmaceuticals (NASDAQ: KERX) on potential catalysts and improving ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE